Cougar Biotechnology to Present at Citi Biotech Day

Cougar Biotechnology, Inc. (NASDAQ: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at Citi�s 4th Annual Biotech Day on Wednesday, April 1, at 10:40 a.m. EDT in New York City. Mr. Auerbach will provide a company overview and update on the status of Cougar�s current clinical development programs.

Interested investors may access a live audio webcast by visiting the Investor Relations section of the Company�s Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web site and available for 30 days.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar�s oncology portfolio includes CB7630, a targeted inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being tested in a Phase III clinical trial in prostate cancer and a Phase I/II trial in breast cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

Cougar Biotechnology (MM) (NASDAQ:CGRB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024